Medical/Pharmaceuticals
Comirnaty Bivalent Vaccine Arrives in Hong Kong SAR and Macau SAR and Will Soon Be Available to the Local Residents
SHANGHAI, Nov. 28, 2022 /PRNewswire/ -- On November 26, 2022, Shanghai Fosun Pharma (Group) Co., Ltd.("Fosun Pharma", Stock Code: 600196.SH; 02196.HK) announced that the first batch of about 770,000 doses of the Comirnaty Original/Omicron BA.4/BA.5 bivalent vaccine (i.e. Comirnaty Original/Omicro...
2022-11-28 22:59
5122
SeekIn Receives CE-IVD Mark Approval for SeekInCure® Cancer Recurrence Monitoring Kit
First-of-its-kind blood-based pan-cancer recurrence monitoring test SHENZHEN, China, Nov. 28, 2022 /PRNewswire/ -- SeekIn Inc, a leader in blood-based cancer early detection and monitoring technology, today announced CE (Conformité Européenne) Mark approval for SeekInCure® Cancer Recurrence Moni...
2022-11-28 21:00
4136
DetectedX Introduces ImageDx to Transform Image-Based Education at RSNA
Showcases Momentum with New Customers, New Subscriber Options and the Addition ofProfessor László Tabár to the Executive Team CHICAGO, Nov. 28, 2022 /PRNewswire/ -- Building on the successful U.S. launch at the SBI/ACR Breast Imaging Symposium, DetectedX, the leaders in intelligent interactive ...
2022-11-28 21:00
3945
Medeologix Acquires Three Silicon Valley Medical Device CDMO Companies and Establishes One-Stop Shop Mass Production Facilities in Taiwan
NEW TAIPEI CITY, Taiwan, Nov. 28, 2022 /PRNewswire/ -- Medeologix, a Taiwan MedTech CDMO company announces its successful acquisition of three premier medical device manufacturing companies to form an integrated full function service group. The newly formed Medeologix family of companies, with a ...
2022-11-28 21:00
5317
GenFleet Therapeutics to Present Data from Phase I Trial of GFH009 Monotherapy at the 2022 Annual Meeting of American Society of Hematology (ASH)
SHANGHAI and NEW ORLEANS, Nov. 28, 2022 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced the preliminary safety and efficacy data from the Phase I study of GFH009 monotherapy for treatment ...
2022-11-28 19:00
3409
Lyvgen Announces Phase 2 Clinical Collaboration with Bristol Myers Squibb to Evaluate LVGN7409 in Combination with Nivolumab in Non-Small Cell Lung Cancer Patients
* LVGN7409 is a next generation CD40 agonistic antibody; Nivolumab is a PD-1 checkpoint inhibitor; docetaxel is an anti-tubulin chemotherapy agent * Combination study to begin in 1st half 2023 SHANGHAI and SUZHOU, China, Nov. 27, 2022 /PRNewswire/ -- Lyvgen Biopharma, a leading innovative glob...
2022-11-28 07:00
2530
New study on deep learning technology for improving MRI image quality published in European Radiology
SwiftMR™, an AI-powered MRI reconstruction solution from AIRS Medical proved
its performance for enhancing the image quality of 3D high-resolution MRI
SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- A recent study published in
European Radiology
2022-11-25 23:00
13921
Neurophet, to participate in the Radiological Society of North America RSNA 2022
̵ Introducing 4 products at the booth including the main product Neurophet AQUA ̵ Conducting in-depth discussions jointly team members from R&D and cooperation with several global companies SEOUL, South Korea, Nov. 25, 2022 /PRNewswire/ -- Neurophet, an artificial intelligence (AI) solution comp...
2022-11-25 22:00
12974
Chemotherapy may be completed within 8 days with two doses of Polytaxel, an innovative anticancer drug from South Korea's biotech firm
* Polytaxel, a novel pain-free anticancer drug, may not require break periods * A new standard of care, more convenient than docetaxel, is suggested * Hyundai Bioscience to enter clinical trial on pancreatic cancer in Australia * Patient-centered chemotherapy to enable outpatients to live nor...
2022-11-25 21:00
13151
Concord Medical Schedules 2022 Annual Meeting of Shareholders
BEIJING, Nov. 25, 2022 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention by establishing proton centers and cancer hospitals and operating an extensi...
2022-11-25 19:30
12776
Peijia Medical Limited and inQB8 Medical Technologies, LLC report Successful First-in-Human implantation of MonarQ Transcatheter Tricuspid Valve Replacement System
SUZHOU, China, Nov. 25, 2022 /PRNewswire/ -- inQB8 Medical Technologies, LLC (inQB8), in Partnership with Peijia Medical Limited (Peijia, (9996.HK)), announced today that it has successfully implanted the MonarQ Transcatheter Tricuspid Valve in a 75-year-old female suffering from severe torrentia...
2022-11-25 16:00
3408
Mabwell Announces the U.S. FDA approval of 9MW3011 (FIC) for IND
SHANGHAI, Nov. 24, 2022 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with the layout of whole industry chain, announced that its clinical trial application for 9MW3011 Injection used in patients with polycythemia vera was formally approved by the United States Food...
2022-11-24 21:00
5140
AnchorDx Enrolls the First Patient For Its UriFind® Bladder Cancer Assay Clinical Trial in the U.S.
GUANGZHOU, China, Nov. 23, 2022 /PRNewswire/ -- AnchorDx, a world-leading developer of cancer early detection solutions, announced the first patient enrollment for the UriFind® bladder cancer assay clinical trial in the U.S., an over 1,000-patient multi-center, prospective testing of the assay in...
2022-11-23 22:00
4677
Gracell Biotechnologies to Participate in Two Upcoming Investor Conferences
SAN DIEGO, Calif., and SUZHOU and SHANGHAI, China, Nov. 23, 2022 /PRNewswire/ -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to discovering and developing highly efficacious and affordable cell therapies for the treatment o...
2022-11-23 21:00
4924
J INTS BIO, M.D Anderson Cancer Center joint development - oral HSP90 inhibitor 'JIN-001', presentation of preclinical assessment at 2022 SNO Annual Meeting
SEOUL, South Korea, Nov. 23, 2022 /PRNewswire/ -- J INTS BIO announced that the preclinical assessment of JIN-001 or MPT0B640, a novel, orally administered 2nd generation HSP90 (heat shock protein 90) inhibitor, was presented during the 2022 edition of the Society for Neuro-Oncology Conference, h...
2022-11-23 15:18
2465
Jiangsu Traditional Chinese Medicine International Exchange Conference kicked off in Nanjing
NANJING, China, Nov. 23, 2022 /PRNewswire/ -- On November 21st, the "Jiangsu Traditional Chinese Medicine International Exchange Conference" jointly sponsored by the Foreign Affairs Office of Jiangsu Provincial People's Government and Jiangsu Health Commission kicked off inNanjing. The theme of t...
2022-11-23 14:19
2831
Illuccix® Available on High Activity Gallium Generator Technology to Meet High Demand
INDIANAPOLIS, Nov. 22, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces Illuccix® (kit for the preparation of gallium Ga 68 gozetotide injection) with up to 50mCi for radiolabeling is available for use on 100mCi (millicurie) gallium generators, an ...
2022-11-22 20:00
3046
IND approval from the US FDA for theranostic SAR-Bombesin trial in prostate cancer
SYDNEY, Nov. 21, 2022 /PRNewswire/ -- Highlights * Clarity's fifth successful Investigational New Drug (IND) application with theUnited States Food and Drug Administration (US FDA), opening up therapeutic applications for SAR-Bombesin * A total of six products with both the diagnostic and t...
2022-11-21 22:04
4467
United Imaging Drives Forward Several Major Innovations in Multiple Imaging Modalities
The company's IPO and 20,000th global installation are followed by new technological innovations, in keeping with its commitments to the U.S. and other markets. HOUSTON, Nov. 21, 2022 /PRNewswire/ -- United Imaging, a global leader in producing advanced medical imaging and radiotherapy equipment...
2022-11-21 22:00
4075
Lunit Becomes the First Medical Software Company in Asia-Pacific to Become MDR CE and UKCA Certified
* Lunit becomes first software as a medical device (SaMD) company in APAC to become MDR CE and UKCA certified * MDR and UKCA certifications are required for all Europe and UK commercial medical devices with implementation deadlines set to 2024 SEOUL, South Korea, Nov. 21, 2022 /PRNewswire/ --...
2022-11-21 21:00
3673
Week's Top Stories
Most Reposted
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
[Picked up by 320 media titles]
2026-09-03 23:53
TEATER BESAR TAMAN ISMAIL MARZUKI SIMPLIFIES WIRELESS WORKFLOWS WITH SENNHEISER SPECTERA
[Picked up by 283 media titles]
2026-09-03 10:00
A Taste of Thailand: Discover the Spirit of the Elephant at Chang Thai
[Picked up by 282 media titles]
2026-09-03 10:00
From Micro-Weddings to Milestones: Celebrating Life's Special Moments at Four Seasons Resorts of Asia
[Picked up by 282 media titles]
2026-09-04 10:43
OGA 2026 OPENS WITH STRONGER FOCUS ON MARKET ACCESS, REGIONAL PROJECTS AND ENERGY OPPORTUNITIES
[Picked up by 276 media titles]
2026-09-04 01:35
Most Read
Hong Leong Bank Unveils HLB opus Extended Exclusively by Private Invitation
2026-09-03 23:53
9443
FinVolution and NUS Business School share project findings focusing on Financial Inclusion for Filipino Overseas Domestic Helpers at UN Global Compact BRI Summit
2026-09-04 13:11
7279
Physical AI Firm XTEND Set to Make NYSE Trading Debut: NYSE Content Update
2026-09-04 21:14
6491
